secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004193
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx reaffirms Q4/FY2022 sales; warns of Medicare reimbursement risk for skin substitutes
--------------------------------------------------------------------------------

- Q4 2022 net sales expected $73M-$76M; FY2022 $266M-$269M, unchanged from Nov 2022 guidance.
- About 28% of 2022 sales from private physician office; ~75% of that reimbursed by CMS, over 90% is EPIFIX.
- Received FDA TRG letter confirming EPIFIX as Section 361 product in Dec 2022; seeking confirmation for EPICORD.
- Restructuring headcount reductions expected to cut annualized costs by ~$5M; sales force realigned for productivity.
- Entered distribution partnership with Gunze Medical for EPIFIX in Japan; appointed Ricci Whitlow as COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/0001193125-23-004193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/d442188d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer